£1M topical formulation lab expansion investment for MedPharm14 Feb 2018
Expansion will accommodate new scientists to service the increase in demand for the company's formulation development, performance testing and manufacturing services.
MedPharm has announced a laboratory expansion following an internal investment of £1 million to increase its laboratory footprint in the UK by 60%.
The expansion is to accommodate the new scientists needed to service the increase in demand for its formulation development, performance testing and manufacturing services. This increased capacity will allow MedPharm to extend its service offerings across these key areas of expertise.
The expanded facilities will house MedPharm’s two automated testing services, MedStat-HT and MedFlux-HT, which are designed to de-risk client’s development programs and shorten development timelines.
MedFlux-HTis an automated system of 32 flow-through diffusion cells for measuring the in vitro permeation and penetration of drugs into and through human skin (IVPT). It can also be set up with other tissues determined by the medicine’s target site (e.g., mucosal, buccal, etc). The use of MedFlux-HT has been important in the support of patent claims, substantiation of marketing claims for OTC products, new chemical entity development, and development of generic products.
MedStat-HT is an automated system of 24 vertical diffusion cells (VDC) more commonly known as ‘Franz’ or ‘static’ cells for measuring the in vitro release of drug from topical medicines across synthetic membranes (IVRT). Its key benefits are its ability to better characterise formulation drug release properties for potential patent claim support, formulation optimisation and comparison, and potential product quality and stability specifications, with a reduction in experimental time and variability.
“We are very pleased to announce this investment which reflects the trust an increasing number of clients are placing in our services,” commented Dr Andrew Muddle, MedPharm’s co-founder and Chief Executive Officer.
“Our focus on the development topical and transdermal medicines which can benefit developers of new chemical entities, generics or OTC products alike is attracting ever-increasing interest and this expansion will accommodate the demand for our services in the coming years”.
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Lilly to bag Loxo Oncology for $8 billion
8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.Read more
Catalent to double its commercial biomanufacturing capacity
7 Jan 2019
The $200-million expansion will support customers’ development programs and commercial launches.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
Cambrex completes acquisition of Avista Pharma Solutions
2 Jan 2019
Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.Read more
Novartis offers to acquire CellforCure
1 Jan 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.Read more
BMS receives offer from Taisho to purchase UPSA
30 Dec 2018
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.Read more
Recipharm to potentially end operations in Ashton-under-Lyne facility
24 Dec 2018
The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation